Topadur Pharma AG: Innovative medication for the treatment of severe wounds
TOPADUR Pharma Corp. was founded in 2015 by R&D experts with significant experience in pharmaceutical industry. The goal is to focus on research and development of new and innovative drugs for wound healing.
Approach
Diabetic foot ulcer & chronic wounds: TOP – N53
significantly improving microcirculation and fosters angiogenesis at the wound tissue
Scar & keloid prevention: TOP – N44
providing anti-inflammatory and anti-fibrotic effects
Topadur’s lead R&D proprietary programs are local active, highly potent, dual mode of action drugs. Topadur’s unique development candidates work on validated drug targets resulting in higher than average clinical success chances.